Endo International plc (NASDAQ:ENDP) reported on Wednesday the completion of the divestiture of Grupo Farmacéutico SOMAR to Advent International.

The company disposed Grupo Farmacéutico SOMAR to Advent International for a purchase price of about USD124m, after giving effect to estimated cash, debt and net working capital purchase price adjustments.

Following the divestiture of SOMAR complete, Endo looks forward to a continued focus on its core strengths as well as execution against its strategic priorities as a highly focused generics and specialty branded pharmaceutical company, said president and CEO Paul Campanelli.

With global headquarters in Dublin, Ireland and US headquarters in Malvern, PA, Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialisation.